CLINICAL_TRIALS
trial_result
· 2023-03-16
Clinical Trial Update: Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine [Phase 2, Phase 3]
Summary
A long-term safety study of BHV-3500 (zavegepant) for acute treatment of migraine has completed Phase 2/Phase 3 trials with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Acute Migraine | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-03-16